Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Poston

Showing results (321-330 of 353) with videos related to

Pageof 36
Sort By:
The Lancet. Neurology|March 23, 2011
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialPeter A LeWitt, Ali R Rezai, Maureen A Leehey, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 3, 2026
Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal agingJoseph R Winer, Melanie J Plastini, America Romero, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein AggregatesLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
JCI Insight|April 14, 2017
Long-term follow-up of a randomized AAV2-<i>GAD</i> gene therapy trial for Parkinson's diseaseMartin Niethammer, Chris C Tang, Peter A LeWitt, et al.
Cell Reports Methods|April 29, 2025
Accurate prediction of absolute prokaryotic abundance from DNA concentrationJakob Wirbel, Tessa M Andermann, Erin F Brooks, et al.
NPJ Parkinson'S Disease|April 10, 2026
Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein diseaseAlena M Smith, Sara A Lorkiewicz, Burak Arslan, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Pageof 36

Showing results (321-330 of 353) with videos related to

Sort By:
Pageof 36
The Lancet. Neurology|March 23, 2011
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialPeter A LeWitt, Ali R Rezai, Maureen A Leehey, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 3, 2026
Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal agingJoseph R Winer, Melanie J Plastini, America Romero, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein AggregatesLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
JCI Insight|April 14, 2017
Long-term follow-up of a randomized AAV2-<i>GAD</i> gene therapy trial for Parkinson's diseaseMartin Niethammer, Chris C Tang, Peter A LeWitt, et al.
Cell Reports Methods|April 29, 2025
Accurate prediction of absolute prokaryotic abundance from DNA concentrationJakob Wirbel, Tessa M Andermann, Erin F Brooks, et al.
NPJ Parkinson'S Disease|April 10, 2026
Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein diseaseAlena M Smith, Sara A Lorkiewicz, Burak Arslan, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Pageof 36